MOTS-C Research Guide
Mitochondrial and metabolic research peptide
MOTS-c is a 16-amino-acid peptide encoded within the mitochondrial 12S rRNA gene, discovered in 2015 as one of the first identified mitochondrial-derived peptides with systemic metabolic effects. Research has shown it acts as a metabolic regulator targeting AMPK signaling and improving insulin sensitivity in animal models of obesity and aging.
Contents
|
Mitochondrial-derived Encoded in 12S rRNA |
AMPK activation Primary mechanism |
2015 First characterized |
What is MOTS-C?
MOTS-c (mitochondrial open reading frame of the 12S rRNA-c) is a 16-amino-acid peptide encoded within the mitochondrial 12S ribosomal RNA gene. It was first characterized in 2015 by Lee, Wan, and colleagues, becoming one of the founding members of a new class of biologically active peptides known as mitochondrial-derived peptides (MDPs).
Unlike most peptides studied in research, MOTS-c originates from the mitochondrial genome rather than the nuclear genome. This unusual origin reflects an emerging understanding of the mitochondrion as not just an energy-producing organelle but also a signaling hub that produces small peptides with systemic metabolic effects.
Aeternum Labs supplies MOTS-c as a lyophilized powder verified to 99%+ purity by HPLC. Each batch ships with a publicly published Certificate of Analysis tied to the lot number.
Mechanism of action
The primary mechanism of MOTS-c is activation of AMP-activated protein kinase (AMPK), the master cellular energy sensor. AMPK activation by MOTS-c is independent of the cellular AMP:ATP ratio that normally triggers AMPK, suggesting MOTS-c acts through a parallel signaling mechanism.
Downstream of AMPK activation, MOTS-c improves insulin-stimulated glucose uptake in skeletal muscle, reduces hepatic gluconeogenesis, and modulates fatty acid oxidation. The integrated effect in animal studies is improved insulin sensitivity and resistance to diet-induced obesity.
Research has also documented nuclear translocation of MOTS-c under metabolic stress conditions, where the peptide influences nuclear gene expression patterns related to oxidative stress response and mitochondrial biogenesis. This nuclear-mitochondrial signaling role is part of why MOTS-c is studied as a longevity-related compound.
Research history
MOTS-c was characterized in 2015 by Changhan Lee and colleagues at the University of Southern California. The discovery emerged from systematic analysis of small open reading frames within the mitochondrial genome, which had previously been assumed to encode only the standard mitochondrial proteins.
Subsequent research has expanded the published literature on MOTS-c effects in obesity models, type-2 diabetes models, and aging studies. Plasma MOTS-c levels have been shown to decline with age in humans, and lower circulating MOTS-c levels correlate with insulin resistance and metabolic syndrome markers.
More recent work has explored exercise-induced changes in MOTS-c signaling, with evidence that MOTS-c expression and circulation increase with exercise and may mediate some of the metabolic benefits of regular physical activity.
Half-life and pharmacokinetics
MOTS-c has been administered in animal research via intraperitoneal, subcutaneous, and intramuscular routes. Plasma half-life is short (under one hour), but downstream metabolic effects on AMPK signaling and gene expression persist for hours to days after administration.
Tissue distribution research shows MOTS-c reaches skeletal muscle, liver, and adipose tissue in measurable concentrations after systemic administration, consistent with its observed effects on these metabolic tissues.
Typical research doses
Animal research dose ranges in published MOTS-c studies span approximately 0.1 mg/kg to 15 mg/kg per administration. Most metabolic studies use doses in the 0.5-5 mg/kg range with daily or every-other-day frequencies.
Long-term studies use lower doses with sustained administration over weeks to months, consistent with the chronic metabolic adaptations being studied. Acute metabolic challenge studies use higher single doses to assess immediate AMPK signaling responses.
Compliance reminder
All dose ranges discussed are reported from peer-reviewed in vitro and animal research. They are not human-use dose recommendations.
Reconstitution protocol
Lyophilized peptides require reconstitution with a sterile solvent before any in vitro work. The standard solvent across virtually all research-peptide protocols is bacteriostatic water (sterile water with 0.9% benzyl alcohol), which prevents microbial growth across the typical four-week working window once a vial is opened.
Add the solvent slowly down the inside wall of the vial rather than directly onto the lyophilized cake. Swirl gently until the powder dissolves fully. Do not shake — agitation can denature peptide bonds and reduce assay potency. A clear, particle-free solution should result within thirty to sixty seconds.
Volume calculations are straightforward. For a 10 mg vial reconstituted with 2 mL of bacteriostatic water, each 0.1 mL of the resulting solution contains 0.5 mg of peptide. Researchers planning multi-week protocols should compute their volumes ahead of time and document the lot number against each preparation.
Storage and stability
Sealed lyophilized vials are stable at 0°F (−18°C) for up to twenty-four months in most research literature. Vials should be kept dry, light-protected, and away from temperature fluctuations. Avoid storing peptides in the freezer door, where each open-close cycle introduces thermal stress.
Once reconstituted, store the working solution at 36–46°F (2–8°C). Most lyophilized peptides remain stable in solution for twenty-eight days under refrigeration with bacteriostatic water as the diluent. For protocols longer than four weeks, reconstitute fresh batches as needed rather than extending a single working vial.
Repeated freeze-thaw cycles reduce peptide integrity. If long-term storage of a reconstituted sample is required, aliquot the solution into single-use volumes before freezing so each thaw uses a fresh aliquot.
Common stack pairings
MOTS-c + Tesamorelin (metabolic and body composition research)
Tesamorelin’s GH-axis activation and MOTS-c’s AMPK activation target different metabolic regulatory layers. The combination is researched for body composition and metabolic flexibility endpoints.
MOTS-c + NAD+ (mitochondrial and aging research)
Both compounds target mitochondrial function through different mechanisms. NAD+ supports the electron transport chain and sirtuin-mediated regulation, while MOTS-c activates AMPK and modulates mitochondrial biogenesis programs.
How it compares
Compared to direct AMPK activators (e.g., metformin, AICAR): MOTS-c activates AMPK independently of the cellular AMP:ATP ratio, while metformin works through a complex mechanism involving complex I inhibition and AICAR mimics AMP directly. The mechanistic distinction may matter for specific research questions.
Compared to incretin-mimetic metabolic peptides (Retatrutide, semaglutide): incretin peptides act through receptor-mediated effects on insulin secretion and appetite. MOTS-c acts through cellular energy sensing pathways. Different mechanisms may be useful in research designs that need parallel metabolic interventions.
From the Aeternum library
MOTS-C
- 99%+ purity verified by HPLC
- Mass spec sequence confirmation
- LAL endotoxin screening
- Full Certificate of Analysis published
- Lyophilized powder
Frequently asked questions
What does MOTS-c stand for?
MOTS-c stands for Mitochondrial Open reading frame of the Twelve S rRNA-c. It is a peptide encoded within the mitochondrial 12S ribosomal RNA gene, distinguishing it from the vast majority of peptides which are encoded in the nuclear genome.
How does MOTS-c differ from AMPK activators like metformin?
MOTS-c activates AMPK independently of the cellular AMP:ATP ratio. Metformin activates AMPK indirectly through effects on mitochondrial complex I that increase the AMP:ATP ratio. The mechanistic distinction means MOTS-c can produce AMPK signaling without the upstream cellular energy stress that metformin induces.
Why are mitochondrial-derived peptides interesting for research?
The discovery that the mitochondrial genome encodes biologically active peptides expanded the understanding of mitochondria from energy-producing organelles to signaling hubs. MDPs like MOTS-c communicate metabolic state to other tissues and organs, providing a new layer of physiological regulation that is now an active area of research.
What dose ranges are used in research?
Animal research uses 0.1-15 mg/kg per administration, with most metabolic studies in the 0.5-5 mg/kg range. Frequency varies from daily to every-other-day depending on whether the study is investigating acute or chronic effects.
How is MOTS-c stored?
Sealed lyophilized vials are stored at 0°F (−18°C) for long-term stability. Reconstituted working solution is stored at 36–46°F (2–8°C) and used within twenty-eight days.
References
- Lee C, Zeng J, Drew BG, et al. (2015). The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. View source
- Reynolds JC, Lai RW, Woodhead JST, et al. (2021). MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. View source
- Kim KH, Son JM, Benayoun BA, Lee C (2018). The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress. View source
Reviewed by
The Aeternum Labs Research Team
Compounds, COAs, and protocol design
The Aeternum Labs research team verifies every batch in our library against published purity and identity standards. Articles in our research blog summarize publicly available scientific literature and are reviewed for accuracy by team members trained in peptide biochemistry and laboratory protocol design.
Related research
Category
Best peptides for metabolic research →
Category
Best peptides for longevity research →
Pair with
NAD+ research guide →
Pair with
Tesamorelin research guide →
Research Disclaimer. All compounds discussed in this article are sold by Aeternum Labs for in vitro laboratory research purposes only. They are not intended for human or animal consumption, diagnosis, treatment, or prevention of any disease or condition. Information presented is summarized from publicly available scientific literature and should not be construed as medical advice.